×

Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014

LEXINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the Company will release its third quarter financial results on Monday, November 10, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. EST to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427, as well as its partnered programs, including Erivedge® (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the three- and nine-month periods ended September 30, 2014.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 9:00 A.M. EST. The conference ID number is 13258840. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.

About Curis, Inc.

Curis is an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Curis also maintains a license agreement with Debiopharm regarding HSP90 inhibitor Debio 0932. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Michael P. Gray Chief Financial and Chief Business Officer Curis, Inc. 617-503-6632 mgray@curis.com

Source:Curis, Inc.